

# Marc C Smaldone, Mshp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9173082/publications.pdf>

Version: 2024-02-01

29  
papers

773  
citations

567281

15  
h-index

580821

25  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1346  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 897.	7.1	132
2	Competing Risks of Death in Patients with Localized Renal Cell Carcinoma: A Comorbidity Based Model. <i>Journal of Urology</i> , 2012, 188, 2077-2083.	0.4	108
3	Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. <i>European Urology</i> , 2017, 72, 64-75.	1.9	91
4	Coexisting Hybrid Malignancy in a Solitary Sporadic Solid Benign Renal Mass: Implications for Treating Patients Following Renal Biopsy. <i>Journal of Urology</i> , 2014, 191, 296-300.	0.4	49
5	Does Partial Nephrectomy Result in a Durable Overall Survival Benefit in the Medicare Population?. <i>Journal of Urology</i> , 2012, 188, 2089-2094.	0.4	46
6	Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. <i>Cancer</i> , 2015, 121, 3010-3017.	4.1	40
7	Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1663-1669.	1.6	38
8	Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage I-II renal masses: An analysis of the national cancer data base. <i>Cancer</i> , 2018, 124, 3839-3848.	4.1	37
9	Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. <i>Medical Care</i> , 2017, 55, 398-404.	2.4	36
10	Care Transitions between Hospitals are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 1349-1354.	0.4	33
11	Role of radical prostatectomy in metastatic prostate cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 125-134.	1.6	26
12	Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. <i>Cancer</i> , 2017, 123, 1617-1624.	4.1	24
13	The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis. <i>Journal of Urology</i> , 2022, 208, 71-79.	0.4	24
14	The Association of Robot-assisted Versus Pure Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Hospital Costs. <i>European Urology Focus</i> , 2020, 6, 305-312.	3.1	20
15	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 119-125.	5.4	16
16	Increasing Use of Dose-Escalated External Beam Radiation Therapy for Men With Nonmetastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 103-112.	0.8	14
17	The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. <i>Future Oncology</i> , 2016, 12, 687-699.	2.4	9
18	Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e99-e111.	1.9	7

#	ARTICLE	IF	CITATIONS
19	National Trends of Local Ablative Therapy Among Young Patients With Small Renal Masses in the United States. <i>Urology</i> , 2015, 86, 962-967.	1.0	5
20	Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy. <i>Journal of Urology</i> , 2018, 199, 969-975.	0.4	5
21	Functional Parenchymal Volume-based Spectrum Score Is Able to Quantify Ischemic Injury After Partial Nephrectomy. <i>Urology</i> , 2018, 120, 150-155.	1.0	5
22	Treatment delays for muscle-invasive bladder cancer. <i>Cancer</i> , 2019, 125, 1973-1975.	4.1	4
23	Melancholia and cancer: The bladder cancer narrative. <i>Cancer</i> , 2018, 124, 3080-3083.	4.1	2
24	Primary small cell carcinoma of the adrenal gland: Case presentation of a rare extrapulmonary small cell carcinoma. <i>Urology Case Reports</i> , 2020, 33, 101320.	0.3	1
25	Feasibility and Outcomes of Renal Mass Biopsy for Anatomically Complex Renal Tumors. <i>Urology</i> , 2021, 158, 125-130.	1.0	1
26	Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: An analysis from the multi-institutional PURC cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 846.e17-846.e22.	1.6	0
27	EDITORIAL COMMENT. <i>Urology</i> , 2021, 155, 18.	1.0	0
28	Bacillus Calmette-Guérin Packaged for Percutaneous Vaccination Can Be Safely Used for Intravesical Instillation in Patients with Urothelial Carcinoma of the Bladder. <i>Urology Practice</i> , 2020, 7, 487-489.	0.5	0
29	Harnessing choice architecture in urologic practice: Implementation of an opioid-sparing protocol grounded in cognitive behavioral theory. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 95-95.	1.6	0